Avalyn Pharma Inc. Common Stock
NASDAQ:AVLNMedical - Pharmaceuticals
+$0.52 today
- Market cap
- $1.23B
- Beta
- 0.00
Volume 0.40M
Average 0.51M
AVLN Selling, General & Admin
Overhead costs of running the business, including sales, marketing, management, and administrative staff.
Selling, General & Admin history
Currency unavailable · from the income statement
No Selling, General & Admin data reported for this period type.
Selling, General & Admin vs competitors
How AVLN compares with its peers on the latest reported figures
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $893.59M USD | +58.5% | +38.2% | 78.5% | |
| LTM Mar 2026 | $173.21M USD | +78.5% | +16.4% | 48.0% | |
| LTM Mar 2026 | $91.54M USD | +24.6% | +6.3% | 78.2% | |
VCREVicore Pharma Holding AB | LTM Jun 2026 | SEK 48.85M SEK | +20.6% | +21.9% | 3673.4% |
AVLNAvalyn Pharma Inc. Common Stock | — | — | — | — | — |
| Peer median (excluding AVLN) | — | +41.5% | +19.1% | 78.4% | |
Competitors are the stored peer set for AVLN. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Avalyn Pharma Inc. Common Stock
NASDAQ:AVLN
Intrinsic Alpha fair value
Locked
Current Price
$27.69
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.